The U.S. Food and Drug Administration approved on Tuesday Amgen's Bkemv, the first biosimilar to AstraZeneca's rare blood ...
Amgen’s Bkemv is the first interchangeable biosimilar to Soliris to treat certain rare diseases. The treatment of patients ...
Amgen said on Wednesday its drug helped to reduce the risk of flares in patients with an immune system-related condition, ...
Uplizna also hit the target on a number of secondary measures, including: annualised flare rate; flare-free, treatment-free ...
Amgen has made waves in the biosimilar field in recent years with its U.S.-first Humira biosim launch last year and its ...
Amgen announced Phase 3 trial results for Uplizna for IgG4-related disease, achieving an 87% reduction in flare risk. All key ...
Amgen Inc. (NASDAQ:AMGN) has recently been in the news due to its involvement in the promising obesity drug market. Analysts ...
The FDA has made two approvals this week: the first interchangeable biosimilar of Soliris and another indication for Breyanzi ...
According to the findings, the trial met its primary endpoint, demonstrating an 87% decline in flare risk versus placebo.
Share on Facebook. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new ...
A recent IQVIA report found that uptake of biosimilars on the market for at least three years varies from 8% for insulin ...